Stock analysts at Roth Capital assumed coverage on shares of Syros Pharmaceuticals (NASDAQ:SYRS) in a report released on Friday, July 12th, TipRanks reports. The brokerage set a “buy” rating and a $17.00 price target on the stock. Roth Capital’s price objective would suggest a potential upside of 129.73% from the company’s previous close.
Other equities analysts also recently issued research reports about the stock. Piper Jaffray Companies set a $44.00 price objective on shares of First Merchants and gave the company a “buy” rating in a research note on Wednesday, April 10th. ValuEngine downgraded shares of Yirendai from a “sell” rating to a “strong sell” rating in a research note on Wednesday, June 26th. Wedbush reissued an “outperform” rating on shares of Alphabet in a research note on Thursday, April 25th. HC Wainwright reaffirmed a “neutral” rating on shares of Syros Pharmaceuticals in a research note on Thursday, May 2nd. Finally, BidaskClub raised shares of Westport Fuel Systems from a “hold” rating to a “buy” rating in a research note on Friday, July 12th. Two investment analysts have rated the stock with a hold rating and seven have given a buy rating to the company. Syros Pharmaceuticals presently has an average rating of “Buy” and a consensus price target of $16.03.
NASDAQ:SYRS traded down $0.17 on Friday, hitting $7.40. The company had a trading volume of 94,300 shares, compared to its average volume of 180,020. The stock has a market cap of $322.07 million, a PE ratio of -3.87 and a beta of 1.95. The company has a quick ratio of 5.19, a current ratio of 5.19 and a debt-to-equity ratio of 0.02. The company’s 50 day moving average price is $7.18. Syros Pharmaceuticals has a 52 week low of $5.17 and a 52 week high of $13.16.
Syros Pharmaceuticals (NASDAQ:SYRS) last issued its quarterly earnings data on Wednesday, May 1st. The company reported ($0.49) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.57) by $0.08. The business had revenue of $0.45 million during the quarter, compared to the consensus estimate of $0.42 million. Syros Pharmaceuticals had a negative net margin of 3,012.04% and a negative return on equity of 74.28%. As a group, equities analysts expect that Syros Pharmaceuticals will post -1.79 earnings per share for the current fiscal year.
In other news, major shareholder Venture Fund Vii L.P. Arch sold 63,000 shares of the stock in a transaction on Wednesday, July 17th. The shares were sold at an average price of $7.77, for a total transaction of $489,510.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 14.80% of the stock is currently owned by company insiders.
Institutional investors and hedge funds have recently bought and sold shares of the company. D. E. Shaw & Co. Inc. increased its position in shares of Syros Pharmaceuticals by 763.7% during the fourth quarter. D. E. Shaw & Co. Inc. now owns 88,882 shares of the company’s stock worth $496,000 after buying an additional 78,591 shares during the period. BlackRock Inc. increased its position in shares of Syros Pharmaceuticals by 23.1% during the fourth quarter. BlackRock Inc. now owns 1,986,130 shares of the company’s stock worth $11,063,000 after buying an additional 372,462 shares during the period. Nikko Asset Management Americas Inc. increased its position in shares of Syros Pharmaceuticals by 33,768.1% during the first quarter. Nikko Asset Management Americas Inc. now owns 684,475 shares of the company’s stock worth $6,256,000 after buying an additional 682,454 shares during the period. Dimensional Fund Advisors LP increased its position in shares of Syros Pharmaceuticals by 62.3% during the fourth quarter. Dimensional Fund Advisors LP now owns 244,080 shares of the company’s stock worth $1,360,000 after buying an additional 93,728 shares during the period. Finally, Connor Clark & Lunn Investment Management Ltd. increased its position in shares of Syros Pharmaceuticals by 3.3% during the fourth quarter. Connor Clark & Lunn Investment Management Ltd. now owns 122,561 shares of the company’s stock worth $683,000 after buying an additional 3,900 shares during the period. Institutional investors own 56.16% of the company’s stock.
Syros Pharmaceuticals Company Profile
Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatment for cancer and monogenic diseases, and building a pipeline of gene control medicines. Its lead product candidates include SY-1425, a selective retinoic acid receptor alpha agonist, which is in a Phase II clinical trial for genomically defined subsets of patients with acute myeloid leukemia (AML) and myelodysplastic syndrome; SY-1365, a selective cyclin-dependent kinase 7 (CDK7) inhibitor, which is in a Phase I clinical trial that is used for treating patients with solid tumors and blood cancers, including ovarian and breast cancer; and SY-5609, a CDK7 inhibitor, which is in preclinical studies to treat oncology patients.
Featured Story: Accumulation/Distribution
Receive News & Ratings for Syros Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syros Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.